Developing a short form of the Awe Experience Scale (AWE-SF) in psychedelic samples.
Marianna Graziosi, Julia Sarah Rohde, Stephanie Lake, Philippe Lucas, Scott Barry Kaufman, David Bryce Yaden
PLoS One 2024 DOI: 10.1371/journal.pone.0314469 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Validation study Peer reviewed |
|---|---|
| Population | Psychedelic samples |
| Citations | 6 |
| Key points | The AWE-SF is a robust and reliable tool for measuring awe, with facets differentially associated with positive and negative emotional states and psychedelic experiences. |
Abstract
This study aimed to develop and validate a short-form version of the AWE-S (AWE-SF) within psychedelic samples, to reduce participant burden while maintaining psychometric integrity. Across five studies, we first replicated the original six-factor structure of the AWE-S through exploratory and confirmatory factor analyses (Study 1), leading to the creation of the 12-item AWE-SF (Study 2-3). We then established the AWE-SF's initial and predictive validity by correlating it with relevant emotional, psychedelic, and well-being outcomes (Study 4-6). The AWE-SF demonstrated strong positive associations with positive emotions and was also linked to openness to experience. Moreover, the AWE-SF effectively predicted both mystical-type and challenging psychedelic experiences, as well as long-term well-being outcomes such as life satisfaction and psychological richness. In particular, the facets of connection and vastness were associated with positive emotional states and mystical-type experience, while accommodation and self-loss were associated with negative emotional states and challenging psychedelic experience. These findings suggest that the AWE-SF is a robust, reliable, and accessible tool for measuring awe experience.
Citations in the library
Cited by 2
- Psychometric validation of the French version of the five-dimensional altered states of consciousness questionnaire (5D-ASC) and associated 11 OAV subscales. Progress in Neuro-Psychopharmacology and Biological Psychiatry June 20, 2026
- From awe to anxiety: investigating art-induced self-transcendence using virtual reality. Frontiers in Psychology April 16, 2026
Cites 16
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later Journal of Psychopharmacology May 30, 2008
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
and 11 more in the library